RE:Pancreatic Cancer Treatment Benefit-Cost AnalysisAnother dreamland post.....I have held this dog for 5 years....others are here for 20.....the analysis you post here could be conducted by any of the hedge funds that cover the biotech world......the bottom line is we are trading at 1,20....there is a reason for this...we retail investors may not know it....but something is keeping the big money from entering here...is it that a biomarker limits the number of eligible patients....is it that the results are truly not that breathtaking to those in the know? who knows all i know is this is sitting at 1.20....and i dont think any of us is wiser than the analysts who study this....we are just silly dreamers....who will end up broke